Dr. Kian-Huat Lin received his MD degree from the National Taiwan College of Medicine and his PhD from Duke University.  Following an internal medicine residency and clinical hematology oncology fellowship at Washington University (WU), he pursued postdoctoral research under the mentorship of Louis Staudt at the NIH, where he studied MyD88 and NFkB signaling in lymphoid malignancies.  This work led to a co-first author paper in Nature describing activating mutations of MYD88 in lymphoma.  He returned to WU in as Assistant Professor on the tenure track in 2020.  He was granted tenure and promoted to Associate Professor in Medicine and named director of the GI oncology program in the Siteman Cancer Center in 2020. Dr. Lin has established a national reputation as a leader in the field of basic/translational research in pancreatic cancer. He is principal investigator of the recently funded Pancreatic Cancer SPORE at WU. Indeed, he has an outstanding record of continuous extramural funding.  In addition to the SPORE, he currently is principal investigator of two RO1s, and an R37. Dr. Lin’s independent research is focused on charactering mechanisms of therapeutic resistance in pancreatic cancer.  His group was the first to identify the importance of the MK2/Hsp27 axis as a survival factor in pancreatic cancer cells under genotoxic stress (Science Translational Medicine, 2021). This observation has led to an investigator-initiated NIH RO1-funded clinical trial of a MK2 inhibitor in pancreatic cancer.  In summary, Dr. Lin is a physician-scientist with an outstanding record of productivity in pancreatic cancer translational research.  He is an exceptional candidate for ASCI membership.